Abstract. Glioma cells are characterized by their invasiveness and resistance against conventional therapeutics. Telomerase activity has been suggested to be an important target for glioma treatment. Here we assessed the anticancer effects and its potential mechanisms of lentiviral vector mediated siRNA knock-down of the human telomerase reverse transcriptase (hTERT) in U87MG human glioblastoma cells. Stable expression of anti-hTERT siRNA reduced the hTERT expression and TRAP assay telomerase activity to barely detectable levels. Injection of lentiviral vectors encoding anti-hTERT siRNA significantly inhibited the growth of preestablished macroscopic xenograft tumors, which was in contrast to the finding that no obvious effects on cell growth, cell cycle progression and telomere length were observed in anti-hTERT siRNA expressing U87MG cells during short-term in vitro cultures. The in vivo glioma growth inhibition effect was already evident in the period coincided with no detectable telomere length changes, suggesting that hTERT inhibition may hinder glioma cell growth in a telomere length-independent manner. Importantly, transwell migration assay showed profound inhibitory effect on the invasive capacity of U87MG cells following short-term anti-hTERT siRNA expression. Thus, efficient knock-down of hTERT can inhibit glioma cell proliferation and migration prior to its effect on telomere length.
Introduction
Gliomas are the most aggressive type of primary intracranial tumors and constitute almost 80% of primary brain tumors. Patients suffering from malignant gliomas have a life-span between 9 and 12 months after diagnosis. Presently, the conventional treatments for gliomas include surgery, radiation therapy, and chemotherapy. Although a great deal of effort has been directed toward the therapy, the prognosis of gliomas, in particular the high-grade malignant gliomas, has not achieved any marked improvement. The main reason for the poor prognosis is due to the fact that glioma cells migrate across the rim of tumors and infiltrate 'normal brain tissues', and the conventional therapies cannot selectively kill these invasive glioma cells. Therefore, there is an urgent need to develop new therapeutic strategies for malignant gliomas (1, 2) .
Similar to other tumors, gliomas are caused by mutations that activate oncogenes and/or switch off tumor suppressor genes. Overcoming telomere-dependent replication senescence can also be a critical step in glioma development. Telomerase is a ribonucleoprotein enzyme complex, whose RNA component (hTR) is used as a template by the human telomerase reverse transcriptase (hTERT) for synthesizing the telomeric repeat sequences (TTAGGG)n. This lengthens telomere and critically contributes to cellular immortality. Telomerase is expressed in more than 90% of advanced cancers but is not found in most normal cells (3) (4) (5) . Previous studies have shown that inhibition of telomerase activity or downregulation of telomerase expression can inhibit glioma cell proliferation (6, 7) .
It has been demonstrated that telomerase activity is predominantly regulated by hTERT expression (8) and the expression of hTERT is elevated in high-grade gliomas compared to in low-grade gliomas (9, 10) . Thus, hTERT likely plays an important role in the development and progression of gliomas, and may also be a potential target for human malignant glioma treatment using gene therapy approach.
The current study was designed with the aim to investigate the effects of small interfering RNA (siRNA) directed against hTERT (hTERT-siRNA) on glioma cell growth and its invasive capacity. We used VSV-G pseudotyped lentiviral vector mediated delivery of hTERT-siRNA to downregulate hTERT expression in human glioblastoma cell line U87MG. We found that the hTERT-siRNA markedly reduced the hTERT expression and telomerase activity. Functionally, reduced hTERT expression resulted in impaired invasive capacity and inhibited the growth of pre-established macroscopic xenograft gliomas in a telomere length-independent manner.
Materials and methods
Engineering of lentiviral vector based siRNA construct against hTERT. The lentivirus system consisting of pLVTHM, pCMVdR8.74 and pMD2G was obtained from Trono Laboratory (University of Geneva, Switzerland) (11). The pLVTHM vector contains an H1 promoter controlled expression cassette for short hairpin RNAs (shRNAs) and an EF1 promoter controlled GFP expression cassette. The pCMVdR8.74 encodes the regulatory DNA sequences for vector generation and the pMD2G encodes the VSV-G gene. A 19-bp fragment within the hTERT cDNA was chosen as the target for our siRNA (hTERT-siRNA): 5'-GTCTGCCGTTG CCCAAGAG-3' at position 569-588 (Genbank accession no. NM_003219). The expression level of hTERT mRNA in transfected 293T cells was found to be 22.7% of the level in non-transfected cells. Lentiviral vector carrying a scrambled fragment (5'-TTCTCCGAACGTGTCACGT-3') as a negative control (NC) was also generated, which we named hTERT-NC (Fig. 1) . The hTERT-siRNA and the hTERT-NC vector were generated in 293T cells upon transfection of pCMV-dR8.74, pMD2G and shRNA encoding pLVTHM using Lipofectamine 2000 (Invitrogen, USA), according to the manufacturer's instructions. Forty-eight hours post transfection, the viral supernatant was collected and centrifuged at 25,000 rpm, 4˚C, for 90 min, and the pellet was suspended in PBS and stored at -70˚C. Viral titers were determined as transduction unit (TU) by infection of 293T cells with serial dilutions of vector preparation and microscopic counting of GFP expressing colonies as described previously (12) .
Cell culture and lentiviral vector infection. The U87MG human glioma cell line (kindly provided by Dr Jianhong Zhu, Neurosurgical Department of Huashan Hospital, Shanghai, P.R. China) was maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum and antibiotics (penicillin at 100 U/ml and streptomycin at 100 μg/ml) in a humidified atmosphere of 5% carbon dioxide and 95% air at 37˚C. Viral stocks were diluted in serum-free medium to obtain the desired multiplicities of infection (MOI) and added to cell monolayer and incubated at 37˚C for 1 h. The culture medium with 10% fetal calf serum was then added, and the cells were incubated for desired durations. U87MG cells were infected at various MOI and the infection-efficiency curve at 72 h was determined by counting GFP positive cells. In general, the cell infection was dose-dependent in the range of 25-200 MOI. More than 80% of infected cells were obtained at 50 MOI for U87MG cells after 72 h; so cells were infected at 50 MOI in studies described in Figs. 2-6.
Detection of hTERT mRNA expression by reverse transcriptionpolymerase chain reaction (RT-PCR).
Total RNA was isolated from cells infected with the hTERT-siRNA or the hTERT-NC vector or from uninfected cells, using an RNA Isolation Kit (Qiagen, USA), and converted to cDNA with random primer by ExScript™ RT reagent Kit (Takara). PCR reactions were carried out using Ex Taq hot start polymerase (Takara). GAPDH was used a control for adjusting the relative amounts Figure 1 . Construction of the pLVTHM vector encoding anti-hTERT siRNA. For the hTERT-siRNA and the hTERT-NC vector, two single strand DNA encoding two linkers, the target sequences and a loop element were synthesized (Invitrogen). These were annealed to double strand DNA, and ligated into the pLVTHM following MluI and CalI digestion. The vectors were generated by transient transfection of pCMV-dR8.74, pMD2G and the siRNA encoding pLVTHM into 293T cells as described in Materials and methods.
of total RNA between the samples. The thermal cycles were: 94˚C for 1 min, 60˚C for 1 min, and 72˚C for 1 min for 30 cycles for GAPDH (450 bp) and 94˚C for 1 min, 58˚C for 1 min, and 72˚C for 1 min for 36 cycles for hTERT (145 bp). The primers (Invitrogen, Shanghai, P.R. China) used for PCR were as follows: GAPDH, 5'-CTCAGACACCATGGGGAA GGTGA-3' (forward) and 5'-ATGATCTTGAGGCTGTTGT CATA-3' (reverse); hTERT, 5'-CGGAAGAGTGTCTGGAG CAA-3' (forward) and 5'-GGATGAAGCGGAGTCTGGA-3' (reverse) (13) . The PCR reactions for GAPDH and hTERT were mixed in a ration of 1:1 and fractionated on a 3% agarose gel containing 0.5 mg/ml ethidium bromide. Gels were visualized by Gel Doc™XR gel documentation system (Bio-Rad).
Telomerase activity assay. Telomerase activity was measured by polymerase chain reaction (PCR)-based telomeric repeat amplification protocol (TRAP) assay (14) by means of the TRAPeze Telomerase Detection Kit (Chemicon). The enzyme activity products were amplified by PCR and resolved on 10% polyacrylamide gel. Cellular protein extracts were also incubated at 85˚C for 10 min to test their heat sensitivity. A TSR8 PCR positive control and a primer-dimer/PCR contamination control were included in each set of TRAP assays. VA, USA) and analyzed with Revelation™ QuickLink Software. All experiments were performed at least three times with representative data presented.
Measurement of cell growth.
Flow cytometric cell cycle analysis. Cell cycle analysis was performed on day 7 after lentiviral vector infection. Cells were fixed with 70% ethanol and incubated with ribonuclease A (250 mg/ml, Sigma) for 1 h at room temperature and propidium iodide (50 mg/ml, Sigma) for 10 min. Each sample was filtered through a 50-μm nylon mesh to obtain single-cell suspension. The samples were then analyzed on FACSCalibur (Becton Dickinson, Mountain View, CA, USA) with a minimum of 20,000 events recorded. ModFit LT software (Becton Dickinson) was used for data analysis. Mean peak fluorescence was determined for each histogram. Three separate experiments were performed.
Telomere length analysis by fluorescence in situ hybridization. On day 7 after lentiviral vector infection, we hybridized a Cy 3 labeled peptide nucleic acid (PNA) probe (CCCTAA) 3 specific for mammalian telomeres (Applied Biosystems, USA)
to the cells fixed with methanol: acetic acid (3:1), at 72˚C for 8 min. To remove non-hybridized PNA probes, slides were washed with PBS containing 0.05% Tween-20 at 56˚C for 20 min, counterstained with DAPI (60 ng/ml) for 5 min and visualized using an Olympus BX61 fluorescence microscope. In addition, to obtain more precise telomere signals, we performed Z-Stack™ by SPOT-AX system, which detects probe signals in different focal planes and then combines them into a single 2-D projection. The data were analyzed by CytoVision 3.6 and this assessment is only performed in GFP expressing cells.
Cell invasion assay. In vitro invasive capacity was evaluated using CytoSelect™ 24-well Cell Invasion Assay Kit (Cellbiolabs, USA). The basement membrane layer of the cell culture inserts was rehydrated with 300 μl warm (37˚C), serum-free media for 1 h. Seventy-two hours post infection, the cells were harvested and resuspended in serum-free DMEM. The upper chambers of the inserts were filled with 300 μl cell suspension at a cell density of 5x10 6 cells/ml. DMEM (500 μl) containing 10% fetal bovine sera was placed in the lower chambers as chemoattractant. The chambers were incubated at 37˚C in a humidified atmosphere of 5% carbon dioxide for 48 h. Cells that did not migrate through the pores were removed by scraping the membrane with a cotton swab, and those passing through the membrane were fixed in 70% ethanol and stained with hematoxylin and eosin. After microscopic documentation, hematoxylin and eosin stained cells were extracted and measured for optical density at 560 nm in a microplate reader. Three separate experiments were performed. 
B
cutaneously into 24 BALB/c-A nude mice (4 weeks old, SLAC laboratory animal Co. Ltd., Shanghai, P.R. China). When the tumors were 5 mm in diameter, the mice were divided into three groups with 8 animals in each, injected with 5x10 7 TU of either the hTERT-siRNA (U87-I) or the hTERT-NC (U87-E) vector in 10 μl PBS, or 10 μl PBS (control U87 group). The length and width of the tumors were measured every third day, and the tumor mass was calculated using the equation 0.5 x length x width 2 (15) . All measurements were performed in a coded, blinded fashion. Mice were sacrificed 27 days later, and tumors were dissected to determine telomerase activities by TRAP assay and to examine the expression of hTERT mRNA by RT-PCR analysis. The Ethics Committee of the Nanjing Medical University, China has approved the animal experiments for this study.
Statistical analysis. Data were analyzed with Stata 7.0. The mean differences among the three groups were tested using ANOVA, followed by multiple comparisons with the Scheffe method. Statistical significance was assigned to P<0.05.
Results

Lentiviral vector mediated delivery of hTERT-siRNA inhibits hTERT expression and telomerase activitiy in vitro and in vivo.
The pLVTHM vector allows stable transduction of shRNAs that are then processed to siRNA in mammalian cells. Oligonucleotides encoding shRNAs complementary to hTERT were cloned into pLVTHM. Three days after vector infection, cells were collected and examined for hTERT mRNA expression and telomerase activity. As shown in Fig. 2 upper part, hTERT mRNA expression diminished to barely detectable levels in the U87MG cells infected with the hTERT-siRNA vector, compared to the cells infected with the control hTERT-NC vector or the uninfected control cells. Similar data were achieved in U87MG cell xenograft gliomas in mice following injection with the hTERT-siRNA vector (Fig. 2 lower part) . Accordingly, reduction of hTERT mRNA expression resulted in severely diminished TRAP assay telomerase activity (Fig. 3) . Fig. 4A , a 7-day short-term in vitro culture showed no measurable differences on the growth rate between the U87MG cells infected with the hTERT-siRNA, the hTERT-NC vector or the uninfected U87MG cells. To determine if downregulation of hTERT affects cell cycle of malignant glioma cells, the flow cytometric analysis for cellular DNA content was performed on day 7 after infection. As shown in Fig. 4B , the G2/M phase percentages in the parental U87MG cells and the cells infected with the hTERT-NC vector were 64.9 and 65.3%, respectively, while the hTERT-siRNA vector infected cells contained 67.3% cells in G2/M phase. The S-phase fraction in parental U87MG cells and cells infected with the hTERT-NC vector was 14.4 and 13.6%, respectively, but in the hTERT-siRNA vector infected cells the value decreased slightly to 11.7%. No significant differences were observed in the proportion of G0/G1 fractions among the three groups and a sub-G0/G1 fraction was not detected, indicating that apoptosis did not occur within the time frame. These results suggest that under our short-term in vitro conditions, siRNA mediated downregulation of hTERT did not induce obvious cell cycle progression arrest or cell proliferation inhibition.
Effects of hTERT downregulation on short-term in vitro growth of U87MG cells. As shown in
Effects of hTERT downregulation on telomere length of U87MG cells. For telomere specific FISH, we used Cy 3 directly labeled PNA probes that can hybridize to complementary telomere repeats under conditions of low ionic strength, favoring annealing of the probes but disfavoring renaturation of DNA strands (16) . Therefore, the fluorescence intensity of a given telomere spot is positively correlated with its corresponding repeat lengths. With the image analysis software CytoVision 3.6, the integrated fluorescence intensity values for each cell can be calculated. In the hTERT-siRNA and the hTERT-NC vector infected groups, only the cells that expressed GFP were counted. For each group, at least 100 cells were analyzed (Fig. 5) , the average fluorescence intensity of telomere signals of U87MG cells infected with the hTERT-siRNA, the hTERT-NC vector and the uninfected cells were 27.6±14.4, 27.9±13.9, 29.2±14.6, respectively, and there was no significant difference between them (P>0.05).
Effects of hTERT downregulation on the invasive capacity of U87MG cells.
As cell invasiveness is an important feature of glioma cells, the potential effect of hTERT-siRNA on the invasive capacity of U87MG cells was determined. The transwell membrane was coated with a uniform layer of basement membrane matrix solution that forms a barrier similar to the mammalian basement membrane, thus this system enables the study of cell invasive capacity in vitro. The cells that migrated through the transwell membrane were first stained and then photographed. Subsequently, migrated cells were extracted and OD560 determined for quantification. The OD values were 0.46±0.01, 0.83±0.07 and 0.83±0.05 for the hTERTsiRNA, the hTERT-NC vector infected cells and the control U87MG cells, respectively (Fig. 6) . As the OD560 value is positively correlated to the cell number, the results indicated that the number of the cells invading through transwell membrane was significantly reduced in hTERT-siRNA group compared with that in the hTERT-NC vector infected or the non-infection group (P<0.05), and there was no significant difference between the hTERT-NC vector infected and the uninfected U87MG cells (P>0.05). Thus, downregulation of hTERT expression resulted in a dramatically reduced invasive capacity of U87MG cells.
Effect of hTERT-siRNA on U87MG cell tumor growth in vivo.
To study the potential effects of lentiviral vector delivered hTERT-siRNA on glioma cell growth in vivo, the hTERTsiRNA and the hTERT-NC vector preparation were injected into subcutaneously established U87MG cell xenograft gliomas in immunodeficient mice. As shown in Fig. 7 , the tumors injected with the hTERT-siRNA vector grew significantly slowly, compared with the tumors injected with the hTERT-NC vector or PBS controls. There was no detectable difference in the growth profiles between the tumors injected with the control hTERT-NC vector and the tumors injected with PBS, suggesting that the in vivo glioma cell growth inhibition effect was specific to the delivery of hTERT-siRNA. Importantly, the in vivo glioma cell growth inhibition was already evident at day 6 post vector injection; the averages of tumor volume were 269.64±111.02 mm 3 , 761.82±114.77 mm 3 and 984.41±716.9 mm 3 for the hTERT-siRNA vector, the hTERT- 
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NC vector and the PBS injected U87 group, respectively (P<0.05). The trend was maintained and was significant even at the end of the experiment at day 27 post vector injection.
Discussion
In the present study, we have engineered lentiviral vector encoding siRNA construct targeting hTERT mRNA. The lentiviral vectors were pseudotyped with VSV-G envelope and could mediate efficient gene delivery and maintain longterm transgene expression in normal cells from the central nervous system (17) and in glioma cells (12) . Using U87MG cells as a model, we demonstrated that the hTERT mRNA and telomerase activity were significantly diminished following lentiviral vector mediated delivery of anti-hTERT siRNA. However, under our short-term in vitro culture conditions, diminished hTERT mRNA and telomerase activity showed no detectable effects on cell proliferation, cell cycle progression and telomere sequence shortening. In contrast, a profound reduction in the invasiveness capacity was observed as demonstrated in transwell migration assay. Lentiviral vector mediated delivery of anti-hTERT siRNA in vivo significantly inhibited the growth of pre-established U87MG cell xenograft glioma in immunodeficient mice. Importantly, our data strongly suggest that the inhibition of glioma cell invasion capacity and in vivo growth operated in a telomere length-independent manner. Telomerase complexes, with its hTERT and hTR as essential components, have been suggested to be a key target for cancer treatment (18) . In fact, clinical studies have shown that the presence of telomerase activity in glioma specimens may be a predictor of its malignancy potential (19) (20) (21) and the relative amount of hTERT mRNA may represent a diagnostic and prognostic indicator for GBM patients (9) . Moreover, high level hTERT mRNA or high telomerase activity is associated with rapid tumor recurrence and/or poor therapeutic outcome in many other human tumors (22) (23) (24) .
Previous studies have shown that downregulation of hTERT can lead to declined cell proliferation and/or induction of apoptotic cell death in glioma cells and other types of cancer cells (25) (26) (27) (28) (29) (30) (31) . As human cells reduce their telomere length by 5-20 repeats during each cell cycle, there will be a lag phase between the onset of telomerase inhibition and the stage when cancer cell telomere sequences are sufficiently shortened to generate detrimental effects on chromosomal segregation during mitosis (18) . Therefore, if the cell growth inhibition effect is telomere length-dependent, long-term suppression of telomerase expression will be required until cell growth inhibition could be evident (32) . On the other hand, recent studies have suggested that hTERT contributes to tumorigenesis by a telomere length-independent mechanism (33). In line with this, siRNA mediated downregulation of RNA unit rapidly inhibited the cell growth and enhanced cell apoptosis in multiple types of cancer cells in a telomere length-independent manner (34, 35) . In agreement with previously studies (27, 28) , our data show that although hTERT mRNA and TRAP assay telomerase activity are diminished following lentiviral vector mediated delivery of anti-hTERT siRNA, the short-term in vitro growth capacity of such cells are not impaired. However, the in vivo glioma cell growth was significantly inhibited. But our data strongly suggest that the anti-hTERT siRNA mediated in vivo glioma cell growth inhibition effect is not due to telomere length shortening, because a significant growth inhibition was already detected at day 6 post lentiviral vector injection, a time period not sufficient for inducing telomere length shortening as assessed in in vitro infected glioma cells. Thus, anti-hTERT siRNA mediated in vitro and in vivo cancer cell growth inhibition can operate via different mechanisms.
Although remote metastasis is rare for glioma, intracranial infiltration of glioma cells represents a determining factor for the dismal treatment outcome. Our data also show that inhibition of hTERT can critically reduce the invasive capacity of glioma cells. Thus, inhibition of hTERT can reduce glioma cell proliferation as well as invasive capacities. Our findings are consistent with findings that the components of telomerase complexes are also involved in gene expression related to cancer cell proliferation and migration and also the angiogenesis process (35) . To our knowledge, this is the first report demonstrating a direct involvement of hTERT in cell migration capacity. Further studies are required to clarify the mechanism for the finding of these studies.
In conclusion, we have demonstrated that lentiviral vector mediated stable expression of hTERT targeting siRNA can significantly inhibit the in vivo glioma cell growth in a telomere length-independent manner. Importantly, the inhibition of hTERT results in diminished invasive capacity in glioma cells. Thus, inhibition of hTERT may greatly improve the outcome of glioma treatment, and when used in combination with other measures may contribute towards a better clinical prognosis. 7 U87MG glioma cells were transplanted subcutaneously into BALB/c-A nude mice. When the tumors were 5 mm in diameter, 5x10 7 TU of either the hTERT-NC (U87-E), the hTERT-siRNA (U87-I) vector in 10 μl PBS, or 10 μl PBS (U87) were injected into the tumor. The ability of the hTERT-siRNA to inhibit tumor growth in vivo was determined by measuring tumor volume every third day. Tumor size was calculated using the equation: 0.5 x length x width 2 . All measurements were performed in a coded, blinded fashion.
